Investing Port

P/S	31.2
P/BV	5.85
EV/EBITDA	-8.03
EBITDA	-0.29
Цена ао	46.94

Institutions	Объем	Доля, %
First Trust Portfolios L.P.	45691	0.07
Hennion & Walsh, Inc	500	0
Janus Capital Management LLC	5996305	9.7
Logos Global Management LP	850000	1.38
Nicholas Investment Partners	11983	0.02
Asymmetry Capital Management, L.P.	155232	0.25
CT Mason	124749	0.2
Security Investors, LLC	80430	0.13
Fernwood Investment Management, LLC	187477	0.3
Perceptive Advisors LLC	5800996	9.39
First Midwest Bank	14582	0.02
John Hancock Investment Management LLC	221913	0.36
Botty Investors LLC	217510	0.35
Fidelity Management & Research Company LLC	3717701	6.02
Pharmakon Advisors L.P.	653414	1.06
BNP Paribas Asset Management Luxembourg	280239	0.45
AQA Capital Limited	5000	0.01
Fidelity Investments	381839	0.62
Great Point Partners LLC	655676	1.06
Hennion & Walsh, Inc	500	0
Munder Lee Investments Ltd	20405	0.03
Fidelity Management & Research Company LLC	3431107	5.55
Fidelity Investments Canada ULC	25678	0.04

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.